Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430622885/en/

Matthew P. Kowalsky, Chief Legal Officer, Enanta Pharmaceuticals, Inc. (Photo: Business Wire)

“I’m pleased to welcome Matt to Enanta. The breadth of his legal expertise across a wide range of activities in the life sciences industry, including his experience with early and late-stage clinical trials, commercial products, intellectual property, business development and other corporate transactions, makes him an important addition to the Enanta leadership team as we advance toward several important catalysts this year,” commented Jay R. Luly, Ph.D., President and Chief Executive Officer at Enanta Pharmaceuticals. “In addition to his strong expertise and experience, Matt is a proven leader in life sciences, which will support our continued growth as we further our mission of developing important medicines in virology and immunology.”

“I’m proud to join a team with an established track record of success, dedicated to the discovery and development of groundbreaking small molecule drugs in areas of significant unmet medical need,” said Matthew Kowalsky. “With multiple near-term catalysts across the pipeline and a solid cash position, this is an important and transformational time for Enanta. I look forward to collaborating with the seasoned management team to support all initiatives aimed at progressing our pipeline, improving the lives of patients and their caregivers, and enhancing shareholder value.”

Mr. Kowalsky brings more than 20 years of experience handling legal matters across a range of disciplines, including corporate governance, public company reporting, intellectual property, financing, business development and M&A activities in the life sciences industry. Prior to joining Enanta, Mr. Kowalsky held legal and operational roles of increasing responsibility at Sigilon Therapeutics, Inc., until its acquisition by Eli Lilly in 2023. Most recently, he served as the Chief of Staff and Chief Legal and Administrative Officer of Sigilon, which he joined in 2019 as its General Counsel and Corporate Secretary. Prior to Sigilon, Mr. Kowalsky was Vice President of Legal and Corporate Secretary at Proteon Therapeutics, Inc. from 2016 to 2019. Previously, he served as Senior Corporate Counsel at Sanofi Genzyme, supporting business development activities, marketed products and alliances for the rare disease business. Earlier, Mr. Kowalsky held similar roles at Cubist Pharmaceuticals, Inc., ARIAD Pharmaceuticals, Inc. and Lantheus Medical Imaging, Inc., formerly Bristol-Myers Squibb Medical Imaging, Inc. Mr. Kowalsky began his legal career in the corporate and intellectual property groups of Choate, Hall & Stewart LLP. He holds a B.A. from the University of Notre Dame and a J.D. from the Notre Dame Law School. Before attending law school, he served as a surface warfare officer in the U.S. Navy.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for virology and immunology indications. Enanta’s research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus infection (HCV) and is sold by AbbVie in numerous countries under the trade names MAVYRET^®(U.S.) and MAVIRET^®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit http://www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240430622885/en/